Albany Molecular Research, Inc.  

(Public, NASDAQ:AMRI)   Watch this stock  
Find more results for Sanofi US Services Inc
19.34
-0.02 (-0.10%)
Real-time:   11:10AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 19.33 - 19.88
52 week 9.71 - 22.30
Open 19.63
Vol / Avg. 52,098.00/517,441.00
Mkt cap 625.71M
P/E 64.99
Div/yield     -
EPS 0.30
Shares 32.35M
Beta 1.75
Inst. own 87%
Aug 5, 2014
Q2 2014 Albany Molecular Research Inc Earnings Call - 10:00AM EDT - Add to calendar
Aug 5, 2014
Q2 2014 Albany Molecular Research Inc Earnings Release - 9:30AM EDT - Add to calendar
Jun 17, 2014
Albany Molecular Research Inc at Wells Fargo Healthcare Conference
Jun 2, 2014
Albany Molecular Research at Jefferies Global Healthcare Conference
Jun 2, 2014
Albany Molecular Research Inc Conference call to discuss Acquisition of Oso Biopharmaceuticals Manufacturing
May 21, 2014
Albany Molecular Research at UBS Global Healthcare Conference
May 6, 2014
Q1 2014 Albany Molecular Research Earnings Conference Call
May 6, 2014
Q1 2014 Albany Molecular Research Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 5.90% 5.14%
Operating margin 12.58% 8.18%
EBITD margin - 18.28%
Return on average assets 2.97% 3.58%
Return on average equity 5.64% 5.61%
Employees 1,282 -
CDP Score - -

Address

21 CORPORATE CIRCLE, P O Box 15098
ALBANY, NY 12203-5154
United States - Map
+1-518-4640279 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Albany Molecular Research, Inc. (AMRI) is a contract research and manufacturing company. The Company provides customers with fully integrated drug discovery, development and manufacturing services. The Company operates in two segments: Large Scale Manufacturing (LSM) and Discovery, Drug Development and Small Scale Manufacturing (DDS). Its LSM segment activities include pilot to commercial scale production of active pharmaceutical ingredients and intermediates, sterile syringe and vial filling and high potency and controlled substance manufacturing and its remaining activities, including drug lead discovery, optimization, drug development, and small scale commercial manufacturing represent its DDS business segment. In March 2014, the Company acquired Cedarburg Pharmaceuticals Inc. In July 2014, AMRI acquired Oso Biopharmaceuticals Manufacturing, former portfolio company of Altaris Capital Partners, LLC.

Officers and directors

William S. Marth President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Michael M. Nolan Chief Financial Officer, Vice President, Treasurer
Age: 49
Bio & Compensation  - Reuters
George Svokos Senior Vice President - Sales, General Manager - API
Age: 56
Bio & Compensation  - Reuters
Steven R. Hagen Ph.D. Senior Vice President - Manufacturing and Pharmaceuticals
Age: 53
Bio & Compensation  - Reuters
Michael A. Luther Ph.D. Senior Vice President - Discovery Services
Age: 58
Bio & Compensation  - Reuters
Lori M. Henderson Esq. Vice President, General Counsel, Secretary
Age: 52
Bio & Compensation  - Reuters
Thomas E. D' Ambra Ph.D. Non-Executive Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Una S. Ryan Ph.D., OBE Lead Independent Director
Age: 72
Bio & Compensation  - Reuters
Veronica G. H. Jordan Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Gabriel S. Leung Independent Director
Age: 52
Bio & Compensation  - Reuters